Amgen Inc. (NASDAQ:AMGN): The acquisition of Horizon Therapeutics is expected to be completed in the first half of the year

On February 6, Amgen Inc.  (NASDAQ:AMGN) announced its fourth quarter and full year 2022 financial results. For the fourth quarter of 2022, the Company generated total revenue of $6.8 billion and GAAP earnings per share of $3.00, and for the full year 2022, total revenue of $26.3 billion and GAAP earnings per share of $12.11. Amgen said it expects to complete the acquisition of Horizon Therapeutics in the first half of this year.

Scroll to Top